Shots:

• The P-III COLUMBA (NCT03277105) study involves assessing of Darzalex (SC) + recombinant human hyaluronidase PH20 (2000 U/mL) vs Darzalex (IV) in 522 patients with r/r multiple myeloma
• The P-III COLUMBA study results: ORR (41.1% vs 37.1%); geometric mean of Maximum Trough concentration (Ctrough) (499 mg/mL vs 463 mg/mL); no new safety signals
• Darzalex (daratumumab) is IgG1k mAb- with broad spectrum cytotoxic activity targeting CD38 and has received two BT designation from FDA as monothx & combination therapy. In Aug-2012 Janssen Biotech collaborated with Genmab to develop and commercialise daratumumab

Ref: Genmab | Image: Pharma News